Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Stock Position Boosted by Hennion & Walsh Asset Management Inc.

Hennion & Walsh Asset Management Inc. boosted its stake in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) by 18.1% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 863,255 shares of the biopharmaceutical company’s stock after acquiring an additional 132,117 shares during the quarter. Hennion & Walsh Asset Management Inc.’s holdings in Lexicon Pharmaceuticals were worth $638,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Barclays PLC boosted its position in shares of Lexicon Pharmaceuticals by 391.6% during the 3rd quarter. Barclays PLC now owns 193,873 shares of the biopharmaceutical company’s stock valued at $304,000 after purchasing an additional 154,436 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Lexicon Pharmaceuticals by 8.4% during the 3rd quarter. Geode Capital Management LLC now owns 3,523,971 shares of the biopharmaceutical company’s stock valued at $5,534,000 after purchasing an additional 273,436 shares in the last quarter. XTX Topco Ltd bought a new position in shares of Lexicon Pharmaceuticals during the 3rd quarter valued at about $126,000. State Street Corp boosted its position in shares of Lexicon Pharmaceuticals by 6.8% during the 3rd quarter. State Street Corp now owns 2,471,215 shares of the biopharmaceutical company’s stock valued at $3,880,000 after purchasing an additional 157,738 shares in the last quarter. Finally, Atom Investors LP bought a new position in shares of Lexicon Pharmaceuticals during the 3rd quarter valued at about $122,000. Institutional investors own 74.70% of the company’s stock.

Lexicon Pharmaceuticals Price Performance

LXRX stock opened at $0.69 on Tuesday. The company has a current ratio of 7.45, a quick ratio of 7.43 and a debt-to-equity ratio of 0.56. Lexicon Pharmaceuticals, Inc. has a one year low of $0.62 and a one year high of $3.73. The firm has a market capitalization of $169.91 million, a PE ratio of -0.92 and a beta of 1.06. The firm has a 50-day moving average of $0.81 and a two-hundred day moving average of $1.42.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last posted its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported ($0.18) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.01). Lexicon Pharmaceuticals had a negative net margin of 4,109.41% and a negative return on equity of 107.38%. The firm had revenue of $1.75 million for the quarter, compared to analysts’ expectations of $3.14 million. During the same period in the prior year, the company posted ($0.21) earnings per share. On average, analysts forecast that Lexicon Pharmaceuticals, Inc. will post -0.66 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts have recently weighed in on LXRX shares. Leerink Partners set a $6.00 price objective on shares of Lexicon Pharmaceuticals and gave the company an “outperform” rating in a research report on Friday, October 18th. HC Wainwright restated a “buy” rating and set a $6.00 price objective on shares of Lexicon Pharmaceuticals in a research report on Wednesday, November 13th. Finally, Needham & Company LLC restated a “hold” rating on shares of Lexicon Pharmaceuticals in a research report on Monday, December 23rd. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat.com, Lexicon Pharmaceuticals has a consensus rating of “Hold” and a consensus target price of $6.00.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.